Metraipolis › archive › dc_f722df598bd3
Efficacy of Tumor Necrosis Factor-α Inhibitor Adalimumab in Chronic Recurrent Vogt-Koyanagi-Harada Disease — Europe PMC PMID:41471337
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41471337
- DOI
- 10.3390/ph18121848
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-07T23:28:34.880Z
- SHA-256 of the archived text
036dceab57b9ae4cb64de9fcade9d4109c83860a96ac6b923d12ac1b8698ad33- Stable URL of this page
https://metraipolis.com/documento/dc_f722df598bd3
How to cite
Efficacy of Tumor Necrosis Factor-α Inhibitor Adalimumab in Chronic Recurrent Vogt-Koyanagi-Harada Disease — Europe PMC PMID:41471337 — Europe PMC (en), https://europepmc.org/article/MED/41471337 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f722df598bd3 (Metraipolis archive dc_f722df598bd3, sha256 036dceab57b9ae4cb64de9fcade9d4109c83860a96ac6b923d12ac1b8698ad33)
BibTeX
@misc{dcf722df598bd3,
title = {Efficacy of Tumor Necrosis Factor-α Inhibitor Adalimumab in Chronic Recurrent Vogt-Koyanagi-Harada Disease — Europe PMC PMID:41471337},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41471337},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f722df598bd3; sha256 036dceab57b9ae4cb64de9fcade9d4109c83860a96ac6b923d12ac1b8698ad33},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41471337. Agents can read the archived copy with the MCP tool read_document.